These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

318 related articles for article (PubMed ID: 29208671)

  • 1.
    Fang HY; Münch NS; Schottelius M; Ingermann J; Liu H; Schauer M; Stangl S; Multhoff G; Steiger K; Gerngroß C; Jesinghaus M; Weichert W; Kühl AA; Sepulveda AR; Wester HJ; Wang TC; Quante M
    Clin Cancer Res; 2018 Mar; 24(5):1048-1061. PubMed ID: 29208671
    [No Abstract]   [Full Text] [Related]  

  • 2. High-Fat Diet Accelerates Carcinogenesis in a Mouse Model of Barrett's Esophagus via Interleukin 8 and Alterations to the Gut Microbiome.
    Münch NS; Fang HY; Ingermann J; Maurer HC; Anand A; Kellner V; Sahm V; Wiethaler M; Baumeister T; Wein F; Einwächter H; Bolze F; Klingenspor M; Haller D; Kavanagh M; Lysaght J; Friedman R; Dannenberg AJ; Pollak M; Holt PR; Muthupalani S; Fox JG; Whary MT; Lee Y; Ren TY; Elliot R; Fitzgerald R; Steiger K; Schmid RM; Wang TC; Quante M
    Gastroenterology; 2019 Aug; 157(2):492-506.e2. PubMed ID: 30998992
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Notch Signaling Mediates Differentiation in Barrett's Esophagus and Promotes Progression to Adenocarcinoma.
    Kunze B; Wein F; Fang HY; Anand A; Baumeister T; Strangmann J; Gerland S; Ingermann J; Münch NS; Wiethaler M; Sahm V; Hidalgo-Sastre A; Lange S; Lightdale CJ; Bokhari A; Falk GW; Friedman RA; Ginsberg GG; Iyer PG; Jin Z; Nakagawa H; Shawber CJ; Nguyen T; Raab WJ; Dalerba P; Rustgi AK; Sepulveda AR; Wang KK; Schmid RM; Wang TC; Abrams JA; Quante M
    Gastroenterology; 2020 Aug; 159(2):575-590. PubMed ID: 32325086
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Elimination of NF-κB signaling in Vimentin+ stromal cells attenuates tumorigenesis in a mouse model of Barrett's Esophagus.
    Anand A; Fang HY; Mohammad-Shahi D; Ingermann J; Baumeister T; Strangmann J; Schmid RM; Wang TC; Quante M
    Carcinogenesis; 2021 Apr; 42(3):405-413. PubMed ID: 33068426
    [TBL] [Abstract][Full Text] [Related]  

  • 5. EUS followed by EMR for staging of high-grade dysplasia and early cancer in Barrett's esophagus.
    Larghi A; Lightdale CJ; Memeo L; Bhagat G; Okpara N; Rotterdam H
    Gastrointest Endosc; 2005 Jul; 62(1):16-23. PubMed ID: 15990814
    [TBL] [Abstract][Full Text] [Related]  

  • 6. EUS in the management of the patient with dysplasia in Barrett's esophagus.
    Savoy AD; Wallace MB
    J Clin Gastroenterol; 2005 Apr; 39(4):263-7. PubMed ID: 15758616
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immune microenvironment in Barrett's esophagus adjacent to esophageal adenocarcinoma: possible influence of adjacent mucosa on cancer development and progression.
    Gokon Y; Fujishima F; Taniyama Y; Ishida H; Yamagata T; Sawai T; Uzuki M; Ichikawa H; Itakura Y; Takahashi K; Yajima N; Hagiwara M; Nishida A; Ozawa Y; Sakuma T; Kanba R; Sakamoto K; Zuguchi M; Saito M; Kamei T; Sasano H
    Virchows Arch; 2020 Dec; 477(6):825-834. PubMed ID: 32533341
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immune determinants of Barrett's progression to esophageal adenocarcinoma.
    Lagisetty KH; McEwen DP; Nancarrow DJ; Schiebel JG; Ferrer-Torres D; Ray D; Frankel TL; Lin J; Chang AC; Kresty LA; Beer DG
    JCI Insight; 2021 Jan; 6(1):. PubMed ID: 33290281
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CDKN2A-p16 Deletion and Activated KRAS
    Sun J; Sepulveda JL; Komissarova EV; Hills C; Seckar TD; LeFevre NM; Simonyan H; Young C; Su G; Del Portillo A; Wang TC; Sepulveda AR
    Cell Mol Gastroenterol Hepatol; 2024; 17(5):769-784. PubMed ID: 38296052
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictors of Progression to High-Grade Dysplasia or Adenocarcinoma in Barrett's Esophagus.
    Whitson MJ; Falk GW
    Gastroenterol Clin North Am; 2015 Jun; 44(2):299-315. PubMed ID: 26021196
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dendritic cells in Barrett's esophagus carcinogenesis: an inadequate microenvironment for antitumor immunity?
    Somja J; Demoulin S; Roncarati P; Herfs M; Bletard N; Delvenne P; Hubert P
    Am J Pathol; 2013 Jun; 182(6):2168-79. PubMed ID: 23619476
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Methylene blue staining of dysplastic and nondysplastic Barrett's esophagus: an in vivo and ex vivo study.
    Canto MI; Setrakian S; Willis JE; Chak A; Petras RE; Sivak MV
    Endoscopy; 2001 May; 33(5):391-400. PubMed ID: 11396755
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Volumetric laser endomicroscopy in the management of Barrett's esophagus.
    Trindade AJ; Leggett CL; Chang KJ
    Curr Opin Gastroenterol; 2017 Jul; 33(4):254-260. PubMed ID: 28402993
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proinflammatory cytokine and nuclear factor kappa-B expression along the inflammation-metaplasia-dysplasia-adenocarcinoma sequence in the esophagus.
    O'Riordan JM; Abdel-latif MM; Ravi N; McNamara D; Byrne PJ; McDonald GS; Keeling PW; Kelleher D; Reynolds JV
    Am J Gastroenterol; 2005 Jun; 100(6):1257-64. PubMed ID: 15929754
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterizing caspase-1 involvement during esophageal disease progression.
    Barber G; Anand A; Katarzyna Oficjalska ; Phelan JJ; Heeran AB; Flis E; Clarke NE; Watson JA; Strangmann J; Flood B; O'Neill H; O'Toole D; MacCarthy F; Ravi N; Reynolds JV; Kay EW; Quante M; O'Sullivan J; Creagh EM
    Cancer Immunol Immunother; 2020 Dec; 69(12):2635-2649. PubMed ID: 32613271
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression profiles of cancer stem cell markers: CD133, CD44, Musashi-1 and EpCAM in the cardiac mucosa-Barrett's esophagus-early esophageal adenocarcinoma-advanced esophageal adenocarcinoma sequence.
    Mokrowiecka A; Veits L; Falkeis C; Musial J; Kordek R; Lochowski M; Kozak J; Wierzchniewska-Lawska A; Vieth M; Malecka-Panas E
    Pathol Res Pract; 2017 Mar; 213(3):205-209. PubMed ID: 28216140
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aberrant methylation of secreted frizzled-related protein genes in esophageal adenocarcinoma and Barrett's esophagus.
    Zou H; Molina JR; Harrington JJ; Osborn NK; Klatt KK; Romero Y; Burgart LJ; Ahlquist DA
    Int J Cancer; 2005 Sep; 116(4):584-91. PubMed ID: 15825175
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potential application of p53 as an intermediate biomarker in Barrett's esophagus.
    Jones DR; Davidson AG; Summers CL; Murray GF; Quinlan DC
    Ann Thorac Surg; 1994 Mar; 57(3):598-603. PubMed ID: 8147627
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A case of simultaneous esophageal squamous cell carcinoma and Barrett's adenocarcinoma.
    Yamazaki T; Iwaya Y; Iwaya M; Watanabe T; Seki A; Ochi Y; Hara E; Sekiguchi T; Hosaka N; Arakura N; Tanaka E; Hasebe O
    Clin J Gastroenterol; 2016 Aug; 9(4):222-7. PubMed ID: 27220657
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Usefulness of insulin-like growth factor II mRNA-binding protein 3 (IMP3) as a new marker for the diagnosis of esophageal adenocarcinoma in challenging cases.
    Kazeminezhad B; Mirafsharieh SA; Dinyari K; Azizi D; Ebrahimi A
    Turk J Gastroenterol; 2014 Jun; 25(3):253-6. PubMed ID: 25141312
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.